Plans, PBMs May Rely Heavily on Prior Authorization for PCSK9 Use

As PBMs look to pit the makers of new PCSK9 inhibitors Praluent (alirocumab) and Repatha (evolocumab) against each other for deep discounts in exchange for preferred or exclusive spots on their formularies, plan sponsors will likely deploy a wide swath of … http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=91A1782D802A41239C8E469F08FB3040&url=https%3a%2f%2faishealth.com%2farchive%2fndbn091115-02&c=hXBgiWdnBDrqT1pvulzKGTNiTQuRLkw2JTk5431gIGo&mkt=en-us